AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32106840 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn Soy Whey Blend w/oil (CSWB w/oil)
Number of subjects: 6112
Study 32106840 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-Use Supplementary Food (RUSF)
Number of subjects: 6112
Study 32106840 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Cereal Plus (SC+)
Number of subjects: 6112
Study 32106874 — intervention group
Group type: EXPERIMENTAL
Intervention: FES-cycling with visual biofeedback plus usual care
Number of subjects: 9
Study 32107021 — intervention group
Group type: EXPERIMENTAL
Intervention: De-novo heart failure (DNHF) hospitalization
Number of subjects: 3362
Study 32107021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular deaths
Number of subjects: 3362
Study 32107021 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cardiovascular deaths
Number of subjects: 3362
Study 32107021 — intervention group
Group type: EXPERIMENTAL
Intervention: Total deaths
Number of subjects: 3362
Study 32107021 — intervention group
Group type: EXPERIMENTAL
Intervention: DNHF hospitalizations
Number of subjects: 3362
Study 32107021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular deaths among DNHF hospitalizations
Number of subjects: 3362
Study 32107021 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cardiovascular deaths among DNHF hospitalizations
Number of subjects: 3362
Study 32107021 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with DNHF
Number of subjects: 3362
Study 32107021 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 3362
Study 32107139 — intervention group
Group type: EXPERIMENTAL
Intervention: Phelan-McDermid syndrome group
Number of subjects: 10
Study 32107139 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 10
Study 32107167 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion-derivative control model applied to a virtual driving task
Number of subjects: 317
Study 32107329 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, cyclophosphamide, and dexamethasone (induction and maintenance)
Number of subjects: 94
Study 32107341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine followed by ofatumumab and ibrutinib
Number of subjects: 66
Study 32107605 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated guidelines on iodinated contrast material
Number of subjects: 1992
Study 32107674 — intervention group
Group type: EXPERIMENTAL
Intervention: General Organizational Index (GOI) scale administered four times over 18 months
Number of subjects: 11
Study 32107712 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg daily)
Number of subjects: 15
Study 32107748 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis (T-T group)
Number of subjects: 0
Study 32107748 — intervention group
Group type: COMPARATOR
Intervention: Tafamidis (P-T group)
Number of subjects: 0
Study 32107748 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (non-Val30Met group)
Number of subjects: 0
Study 32107887 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytical treatment interruption (ATI)
Number of subjects: 16
Study 32108228 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab monotherapy
Number of subjects: 40
Study 32109004 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-h surgery model
Number of subjects: 993
Study 32109483 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing our Hearts, Minds and Bodies (HHMB) intervention
Number of subjects: 260
Study 32109631 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PVT
Number of subjects: 2826
Study 32109631 — intervention group
Group type: COMPARATOR
Intervention: Patients with cirrhosis and AD
Number of subjects: 2826
Study 32109839 — intervention group
Group type: EXPERIMENTAL
Intervention: Mango polyphenols (200-400 g of mango pulp daily for 8 weeks)
Number of subjects: 10
Study 32110025 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate (250-1500 mg/day)
Number of subjects: 97
Study 32110025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 32110060 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (30 mg) administered subcutaneously at Days 0, 28, and 56
Number of subjects: 233
Study 32110060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 32110958 — intervention group
Group type: EXPERIMENTAL
Intervention: Study treatment plans (de-intensified radiotherapy)
Number of subjects: 30
Study 32110958 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment plans (conventional radiotherapy)
Number of subjects: 30
Study 32111348 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral problems associated with a low OHRQoL (GOHAI<50)
Number of subjects: 90
Study 32111358 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO stent PCI
Number of subjects: 3379
Study 32111923 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 1900
Study 32112737 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium-166 radioembolisation
Number of subjects: 30
Study 32112982 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (first-line therapy)
Number of subjects: 150
Study 32113143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosorb hemoperfusion
Number of subjects: 1
Study 32113143 — intervention group
Group type: COMPARATOR
Intervention: IL-6 blockade and methylprednisolone
Number of subjects: 1
Study 32113581 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg/day for 4 days)
Number of subjects: 110
Study 32113581 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (Responders)
Number of subjects: 110
Study 32113581 — intervention group
Group type: COMPARATOR
Intervention: Non-Responders
Number of subjects: 110
Study 32113581 — intervention group
Group type: COMPARATOR
Intervention: Low portal vein pressure group
Number of subjects: 110
Study 32113664 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved EF (pEF, LVEF ≥50%, N = 3526)
Number of subjects: 4005
Study 32113664 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-range EF (mrEF, LVEF 41-49%, N = 302)
Number of subjects: 4005
Study 32113664 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced EF (rEF, LVEF ≤40%, N = 177)
Number of subjects: 4005
Study 32113664 — intervention group
Group type: COMPARATOR
Intervention: Stage C/D heart failure patients (N = 4477)
Number of subjects: 4005
Study 32113892 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral agents (DAAs)
Number of subjects: 1760
Study 32113974 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparetic hand performance in survivors of stroke
Number of subjects: 40
Study 32113974 — intervention group
Group type: COMPARATOR
Intervention: Prestroke dominant hand (DH)
Number of subjects: 40
Study 32113974 — intervention group
Group type: COMPARATOR
Intervention: Prestroke nondominant hand (NH)
Number of subjects: 40
Study 32113974 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength in survivors of stroke
Number of subjects: 40
Study 32114500 — intervention group
Group type: EXPERIMENTAL
Intervention: TriMixDC-MEL IPI (dendritic cell-based mRNA vaccination plus ipilimumab)
Number of subjects: 39
Study 32114500 — intervention group
Group type: EXPERIMENTAL
Intervention: TriMixDC-MEL IPI
Number of subjects: 39
Study 32114500 — intervention group
Group type: EXPERIMENTAL
Intervention: TriMixDC-MEL IPI or subsequent pembrolizumab treatment
Number of subjects: 39
Study 32115672 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA + dextromethorphan (30 mg/day) + memantine (5 mg/day) (DM30 + MM5)
Number of subjects: 66
Study 32115672 — intervention group
Group type: COMPARATOR
Intervention: VPA + Placebo
Number of subjects: 66
Study 32115672 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA + dextromethorphan (30 mg/day) (DM30)
Number of subjects: 66
Study 32115672 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA + memantine (5 mg/day) (MM5)
Number of subjects: 66
Study 32116725 — intervention group
Group type: EXPERIMENTAL
Intervention: Angusta 25 µg
Number of subjects: 72
Study 32116725 — intervention group
Group type: COMPARATOR
Intervention: Cytotec 200 µg
Number of subjects: 72
Study 32116856 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT) with three additional sessions of Intensive Parental Coaching (IPC) after session 4.
Number of subjects: 60
Study 32116856 — intervention group
Group type: COMPARATOR
Intervention: Standard Family-based treatment (FBT) without additional IPC.
Number of subjects: 60
Study 32117045 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 0
Study 32117045 — intervention group
Group type: COMPARATOR
Intervention: First-generation somatostatin analogs
Number of subjects: 0
Study 32117489 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGES Safe Cholecystectomy Program (SCP) rules
Number of subjects: 184
Study 32118001 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 32118001 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32118022 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmalogens treatment, specific dosage and duration not available
Number of subjects: 0
Study 32118022 — intervention group
Group type: COMPARATOR
Intervention: Control group, specific details not available
Number of subjects: 0
Study 32118081 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 90
Study 32118081 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate (BMC)
Number of subjects: 90
Study 32118199 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted active malaria case detection
Number of subjects: 0
Study 32118199 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32118513 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluarix Tetra
Number of subjects: 23939
Study 32118576 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position during sleep
Number of subjects: 148
Study 32118576 — intervention group
Group type: COMPARATOR
Intervention: Prone position during sleep
Number of subjects: 148
Study 32118576 — intervention group
Group type: COMPARATOR
Intervention: Right position during sleep
Number of subjects: 148
Study 32118576 — intervention group
Group type: COMPARATOR
Intervention: Left position during sleep
Number of subjects: 148
Study 32118576 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position versus nonsupine position
Number of subjects: 148
Study 32118582 — intervention group
Group type: EXPERIMENTAL
Intervention: lipoxin A
Number of subjects: 0
Study 32118616 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched, task-specific therapy
Number of subjects: 41
Study 32119924 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Pass Endoscopic Ultrasound-Guided Fine-Needle Biopsy Sample Collection
Number of subjects: 0
Study 32119924 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Pass Endoscopic Ultrasound-Guided Fine-Needle Biopsy Sample Collection
Number of subjects: 0
Study 32119939 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 56
Study 32119939 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 56
Study 32120379 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm group
Number of subjects: 102
Study 32120379 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test
Number of subjects: 102
Study 32120379 — intervention group
Group type: COMPARATOR
Intervention: QT-prolonging medications
Number of subjects: 102
Study 32120379 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison
Number of subjects: 102
Study 32120420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging with position-tracking technology to monitor fetal head station noninvasively throughout labor.
Number of subjects: 613
Study 32121153 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized coagulation service (CS) management
Number of subjects: 2272
Study 32121153 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 2272
Study 32121153 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CS and usual care
Number of subjects: 2272
Study 32122289 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe ESUS (NIHSS ≥6)
Number of subjects: 772
Study 32122289 — intervention group
Group type: COMPARATOR
Intervention: Mild ESUS (NIHSS <6)
Number of subjects: 772
Study 32122334 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritraumatic Dissociative Experiences Questionnaire (PDEQ)
Number of subjects: 647
Study 32122334 — intervention group
Group type: EXPERIMENTAL
Intervention: PDEQ
Number of subjects: 647
Study 32122334 — intervention group
Group type: EXPERIMENTAL
Intervention: PDEQ and other significant risk indicators
Number of subjects: 647
Study 32122345 — intervention group
Group type: EXPERIMENTAL
Intervention: FCH imaging modality
Number of subjects: 0
Study 32122345 — intervention group
Group type: COMPARATOR
Intervention: 3 imaging modalities
Number of subjects: 0
Study 32122366 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 31
Study 32122899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 2 g every 8 h for intravenous bolus injection or 2 g every 12 h for extended infusion over 4 h
Number of subjects: 15
Study 32122899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome during ECMO-ON
Number of subjects: 15
Study 32122899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome during ECMO-OFF
Number of subjects: 15
Study 32122924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazemetostat (EPZ-6438) 800 mg twice a day plus R-CHOP
Number of subjects: 17
Study 32122924 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP alone
Number of subjects: 17
Study 32123139 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to secondhand aerosol from e-cigarettes (SHA)
Number of subjects: 11604
Study 32123139 — intervention group
Group type: EXPERIMENTAL
Intervention: Other indoor settings (e.g., bar and restaurant)
Number of subjects: 11604
Study 32123139 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace/educational venues
Number of subjects: 11604
Study 32123139 — intervention group
Group type: EXPERIMENTAL
Intervention: Home
Number of subjects: 11604
Study 32123139 — intervention group
Group type: EXPERIMENTAL
Intervention: Public transportation
Number of subjects: 11604
Study 32123139 — intervention group
Group type: EXPERIMENTAL
Intervention: Private transportation
Number of subjects: 11604
Study 32123139 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (men, younger age groups, higher education, e-cigarette past users, current smokers, those perceiving SHA harmless, living in higher e-cigarette use prevalence countries)
Number of subjects: 11604
Study 32123534 — intervention group
Group type: EXPERIMENTAL
Intervention: MVM supplementation (single dose on Day 1 and 4-week supplementation on Day 28)
Number of subjects: 82
Study 32123534 — intervention group
Group type: EXPERIMENTAL
Intervention: MVM supplementation (4-week supplementation on Day 28)
Number of subjects: 82
Study 32123534 — intervention group
Group type: EXPERIMENTAL
Intervention: MVM supplementation (single dose on Day 1)
Number of subjects: 82
Study 32124210 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 242
Study 32124317 — intervention group
Group type: EXPERIMENTAL
Intervention: OpenVax computational workflow for identifying somatic variants and predicting neoantigens
Number of subjects: 0
Study 32125175 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 0
Study 32125175 — intervention group
Group type: COMPARATOR
Intervention: BRAFi/MEKi
Number of subjects: 0
Study 32125255 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with specific absorption rate (SAR) measurements
Number of subjects: 0
Study 32125255 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32125711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT)
Number of subjects: 239
Study 32125874 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Ozone Exposure
Number of subjects: 0
Study 32125874 — intervention group
Group type: COMPARATOR
Intervention: Ambient Ozone or Other Pollutants
Number of subjects: 0
Study 32125878 — intervention group
Group type: EXPERIMENTAL
Intervention: Costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI)
Number of subjects: 7
Study 32125937 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg per day for 6 months
Number of subjects: 79
Study 32126141 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab/bendamustine (RB) followed by rituximab/high-dose cytarabine (RC)
Number of subjects: 88
Study 32126156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 113
Study 32126156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Pain (CBT-P)
Number of subjects: 113
Study 32126942 — intervention group
Group type: COMPARATOR
Intervention: Pre-ICH SSRI use
Number of subjects: 2287
Study 32126942 — intervention group
Group type: EXPERIMENTAL
Intervention: New post-ICH SSRI use
Number of subjects: 2287
Study 32126971 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pain by peripheral venous cannulation (PVC) - PVC-Low (NRS ≤ 2)
Number of subjects: 102
Study 32126971 — intervention group
Group type: EXPERIMENTAL
Intervention: PACU nurses' expectations of patients' pain levels
Number of subjects: 102
Study 32126971 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' early pain levels at the PACU
Number of subjects: 102
Study 32126971 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' own forecast of postoperative pain levels
Number of subjects: 102
Study 32126985 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Apps
Number of subjects: 349
Study 32126985 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Apps (Trainees)
Number of subjects: 349
Study 32126985 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Apps (Specialists)
Number of subjects: 349
Study 32126985 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone Peripherals (Trainees)
Number of subjects: 349
Study 32126985 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone Peripherals (Specialists)
Number of subjects: 349
Study 32126985 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Apps Usage (Trainees)
Number of subjects: 349
Study 32126985 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Apps Usage (Specialists)
Number of subjects: 349
Study 32126985 — intervention group
Group type: EXPERIMENTAL
Intervention: Usefulness of Apps
Number of subjects: 349
Study 32126985 — intervention group
Group type: EXPERIMENTAL
Intervention: Usefulness of Peripherals
Number of subjects: 349
Study 32126985 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in Smartphone Peripherals
Number of subjects: 349
Study 32126998 — intervention group
Group type: EXPERIMENTAL
Intervention: PACIC scale (Patient Assessment of Chronic Illness Care)
Number of subjects: 1378
Study 32127922 — intervention group
Group type: EXPERIMENTAL
Intervention: Early systematic supplemental parenteral nutrition (SPN) in combination with nutritional counseling (NC)
Number of subjects: 0
Study 32127922 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counseling (NC) alone
Number of subjects: 0
Study 32128106 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS+OSA (women with PCOS and OSA, ODI ≥ 5)
Number of subjects: 39
Study 32128106 — intervention group
Group type: COMPARATOR
Intervention: PCOS only (women with normal ESS and low-risk Berlin questionnaire, or normal sleep studies, ODI < 5)
Number of subjects: 39
Study 32128228 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-target stool DNA (mt-sDNA) assay (Cologuard)
Number of subjects: 150000
Study 32128249 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (modified classical music) delivered three times a day for 30 minutes with noise cancelation headphones
Number of subjects: 60
Study 32128249 — intervention group
Group type: COMPARATOR
Intervention: Noise cancelation (sham playlist) delivered three times a day for 30 minutes
Number of subjects: 60
Study 32128249 — intervention group
Group type: COMPARATOR
Intervention: Usual care with no specific intervention
Number of subjects: 60
Study 32128326 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid, multipathogen respiratory panel (RP) test
Number of subjects: 191
Study 32128326 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 191
Study 32128723 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical judgement of anesthetic depth by EEG-blinded anesthesiologists
Number of subjects: 600
Study 32128723 — intervention group
Group type: COMPARATOR
Intervention: Narcotrend monitor
Number of subjects: 600
Study 32128723 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical judgement of anesthetic depth
Number of subjects: 600
Study 32128923 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric Bypass
Number of subjects: 2007
Study 32128923 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric Banding
Number of subjects: 2007
Study 32128923 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical Banded Gastroplasty
Number of subjects: 2007
Study 32128923 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 2007
Study 32128975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterascites
Number of subjects: 418
Study 32128975 — intervention group
Group type: COMPARATOR
Intervention: Culture-positive SBP
Number of subjects: 418
Study 32129666 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Initiative to Increase Mother's Own Milk Use
Number of subjects: 0
Study 32129861 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg/day, q8h, IV drip 3 h
Number of subjects: 99
Study 32129861 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/kg/day (continuous infusion)
Number of subjects: 99
Study 32129861 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg/kg/day (continuous infusion)
Number of subjects: 99
Study 32129861 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-160 mg/kg/day
Number of subjects: 99
Study 32130110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fun for Wellness (FFW)
Number of subjects: 461